Pharmaceutical company AbbVie announced Tuesday that it will construct a new $195 million facility near its headquarters in North Chicago.
AbbVie is one of the largest biomedical companies in the world, ranking just below Pfizer in revenue. The company is known for its production of Humira, a treatment for autoimmune diseases such as rheumatoid arthritis and Crohn’s, and Botox.
More Top Picks Longzon 4 In 1
The new facility will be used for the production of active pharmaceutical ingredients, the part of a medication that creates the intended effects. That’s in contrast to inactive ingredients, which are ingredients such as dyes or binding agents that do not contribute to the health effects of the medication.
Construction on the site will begin in the fall and is expected to be finished by 2027. North Chicago is already home to both corporate offices and manufacturing sites for AbbVie, which employ over 11,000 people in Illinois.
The project is in line with Gov. JB Pritzker’s Illinois 2024 Economic Growth Plan, which identifies pharmaceutical manufacturing as an area with “ significant prospects for growth.” The industry provides 260,000 jobs in Illinois, according to the plan.
The expansion is also part of the Illinois Department of Commerce’s Economic Development for a Growing Economy program, which provides benefits for companies committing to investments of $100 million or more in Illinois.
In April, AbbVie publicly committed to investing $10 billion in its U.S. pharmaceutical manufacturing operations from now until 2035.
In May, President Donald Trump issued an executive order directing federal agencies to work to increase domestic pharmaceutical manufacturing. So far, AstraZeneca, Johnson & Johnson and Eli Lily have also committed to billions in domestic pharmaceutical production investments.